VIVANI MEDICAL, INC. Vivani Medical, Inc. Share Price
Equities
VANI
US92854B1098
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 USD | -1.23% |
|
-1.84% | +56.86% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 73.12M 5.76B |
|---|---|---|---|---|---|
| Net income 2024 * | -27M -2.13B | Net income 2025 * | -31M -2.44B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.66
x | P/E ratio 2025 * |
-2.38
x | Employees | 36 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.23% | ||
| 1 week | -1.84% | ||
| Current month | -1.84% | ||
| 1 month | -19.80% | ||
| 3 months | -21.18% | ||
| 6 months | +79.98% | ||
| Current year | +56.86% |
1 week
1.33
1.70
1 month
1.332.09
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 21/05/03 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 29/08/22 |
Truc Le
COO | Chief Operating Officer | 71 | 29/08/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 31/12/08 |
Wilford Baker
BRD | Director/Board Member | 81 | 31/12/20 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 31/12/97 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/24 | 1.33 | -6.99% | 380,400 |
| 17/06/24 | 1.43 | -10.63% | 561,827 |
| 14/06/24 | 1.6 | -1.23% | 739,315 |
| 13/06/24 | 1.62 | -0.61% | 14,740,957 |
| 12/06/24 | 1.63 | 0.00% | 80,426 |
End-of-day quote Nasdaq, June 13, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
27/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.33
USD
Average target price
8
USD
Spread / Average Target
+501.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.86% | 73.12M | |
| +16.43% | 133B | |
| -7.28% | 10.99B | |
| -12.07% | 7.66B | |
| +42.65% | 5.71B | |
| -20.18% | 4.82B | |
| +8.48% | 3.44B | |
| -20.37% | 2.45B | |
| -18.39% | 1.91B | |
| -16.75% | 1.85B |
- Stock Market
- Equities
- VANI Stock
